De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

Lung Cancer

Volumn 99, Issue , 2016, Pages 17-22

  Lucena Araujo, Antonio R ^a,c   Moran, Jason P ^a   VanderLaan, Paul A ^a   Dias Santagata, Dora ^b   Folch, Erik ^a   Majid, Adnan ^a   Kent, Michael S ^a   Gangadharan, Sidharta P ^a   Rangachari, Deepa ^a   Huberman, Mark S ^a   Kobayashi, Susumu S ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Adenocarcinoma; ALK; Crizotinib; Kinase domain; Lung cancer; Mutation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; LUNG CANCER; PRIORITY JOURNAL; ADENOCARCINOMA; CHEMISTRY; DOSE RESPONSE; DRUG RESISTANCE; GENE REARRANGEMENT; GENETICS; HUMAN; LUNG TUMOR; MUTATION; NON SMALL CELL LUNG CANCER; PROTEIN DOMAIN; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84975796838     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.006     Document Type: Article

References (25)

1. [1] Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
2. [2] Soda, M., Choi, Y.L., Enomoto, M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
3. [3] Costa, D.B., ALK inhibitors: plateauing systemic and intracranial activity. Lancet Oncol. 17 (2016), 404–406.
4. [4] Yasuda, H., Figueiredo-Pontes, L.L., Kobayashi, S., Costa, D.B., Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 7 (2012), 1086–1090.
5. [5] Jorge, S.E., Schulman, S., Freed, J.A., et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 90 (2015), 369–374.
6. [6] Costa, D.B., Shaw, A.T., Ou, S.H., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 33 (2015), 1881–1888.
7. [7] Katayama, R., Shaw, A.T., Khan, T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med., 4, 2012, 120ra17.
8. [8] Yamaguchi, N., Lucena-Araujo, A.R., Nakayama, S., et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 83 (2014), 37–43.
9. [9] Costa, D.B., Kobayashi, S., Pandya, S.S., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29 (2011), e443–e445.
10. [10] Friboulet, L., Li, N., Katayama, R., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4 (2014), 662–673.
11. [11] Doebele, R.C., Pilling, A.B., Aisner, D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18 (2012), 1472–1482.
12. [12] Kim, S., Kim, T.M., Kim, D.W., et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 8 (2013), 415–422.
13. [13] Collisson, E.A., Campbell, J.D., Brooks, A.N., Cancer genome atlas research network: comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
14. [14] Yasuda, H., Park, E., Yun, C.H., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med., 5, 2013, 216ra177.
15. [15] Costa, D.B., Halmos, B., Kumar, A., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4 (2007), 1669–1679.
16. [16] de Figueiredo-Pontes, L.L., Wong, D.W., Tin, V.P., et al. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J. Thorac. Oncol. 9 (2014), 248–253.
17. [17] Rangachari, D., VanderLaan, P.A., Le, X., et al. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat. Commun. 4 (2015), 174–181.
18. [18] VanderLaan, P.A., Yamaguchi, N., Folch, E., et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84 (2014), 39–44.
19. [19] Folch, E., Yamaguchi, N., VanderLaan, P.A., et al. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J. Thorac. Oncol. 8 (2013), 1438–1444.
20. [20] Dias-Santagata, D., Akhavanfard, S., David, S.S., et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2 (2010), 146–158.
21. [21] Zheng, Z., Liebers, M., Zhelyazkova, B., et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20 (2014), 1479–1484.
22. [22] Tan, W., Wilner, K.D., Bang, Y., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J. Clin. Oncol., 28, 2010 suppl. abstract 2596.
23. [23] Shaw, A.T., Friboulet, L., Leshchiner, I., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374 (2016), 54–61.
24. [24] Katayama, R., Sakashita, T., Yanagitani, N., et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 3 (2016), 54–66.
25. [25] Zhang, S., Wang, F., Keats, J., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem. Biol. Drug Des. 78 (2011), 999–1005.